# US 2024/0189414 A1 · Engineered heartland virus mrna vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189414 A1
- Document ID: US20240189414A1
- Status: Published application
- Kind: A1
- Application number: 18/530,861
- Filed: 2023-12-06
- Published: 2024-06-13
- Earliest claimed: 2022-12-13
- Assignees: Vernagen, LLC; The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Applicants: Vernagen, LLC; The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Inventors: Baek KIM; Jack Yoon; David Pak; Claire Yuhui Huang Kinney
- Web page: https://patentgrep.com/patent/US20240189414A1

## CPC

- A61K 39/12: Viral antigens
- C07K 14/005: from viruses
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2760/12022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are a Heartland virus vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding Gn or Gc of Heartland virus, a Heartland virus vaccine composition comprising a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding Gn or Gc of Heartland virus fused with human collagen type I alpha 1 (COL1A1) signal peptide, and a method of inducing immune response against Heartland virus by administering an effective amount of the Heartland virus vaccine composition to a subject in need thereof.

## Claims

### Claim 1

A Heartland virus vaccine composition comprising
a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding Gn or Gc of Heartland virus, or the Gn or Gc of Heartland virus fused with human collagen type I alpha 1 (COL1A1) signal peptide.

### Claim 2 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the Gn of Heartland virus has an amino acid sequence of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the Gc of Heartland virus has an amino acid sequence of SEQ ID NO: 2.

### Claim 4 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the Gn of Heartland virus fused with COL1A1 signal peptide has an amino acid sequence of SEQ ID NO: 3.

### Claim 5 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the Gc of Heartland virus fused with COL1A1 signal peptide has an amino acid sequence of SEQ ID NO: 4.

### Claim 6 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the ORF encoding Gn of Heartland virus has a nucleotide sequence of SEQ ID NO: 5.

### Claim 7 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the ORF encoding Gc of Heartland virus has a nucleotide sequence of SEQ ID NO: 6.

### Claim 8 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the ORF encoding Gn of Heartland virus fused with COL1A1 signal peptide has a nucleotide sequence of SEQ ID NO: 7.

### Claim 9 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the ORF encoding Gc of Heartland virus fused with COL1A1 signal peptide has a nucleotide sequence of SEQ ID NO: 8.

### Claim 10 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the mRNA comprising the ORF encoding Gn of Heartland virus further comprises a 5′ untranslated region (UTR), a 3′ UTR, and a poly (A) tail so as to have the following structure:
5′UTR-ORF encoding Gn of Heartland virus-3′UTR-poly (A) tail, and
wherein the ORF encoding Gn of Heartland virus has a nucleotide sequence of SEQ ID NO: 5.

### Claim 11 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the mRNA comprising the ORF encoding Gc of Heartland virus further comprises a 5′ untranslated region (UTR), a 3′ UTR, and a poly (A) tail so as to have the following structure:
5′UTR-ORF encoding Gc of Heartland virus-3′UTR-poly (A) tail, and
wherein the ORF encoding Gc of Heartland virus has a nucleotide sequence of SEQ ID NO: 6.

### Claim 12 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the mRNA comprising the ORF encoding Gn of Heartland virus fused with COL1A1 signal peptide further comprises a 5′ untranslated region (UTR), a 3′ UTR, and a poly (A) tail so as to have the following structure:
5′UTR-ORF encoding Gn of Heartland virus fused with COL1A1 signal peptide-3′UTR-poly (A) tail, and
wherein the ORF encoding Gn of Heartland virus fused with COL1A1 signal peptide has a nucleotide sequence of SEQ ID NO: 7.

### Claim 13 (depends on 1)

The Heartland virus vaccine composition according to claim 1, wherein the mRNA comprising the ORF encoding Gc of Heartland virus fused with COL1A1 signal peptide further comprises a 5′ untranslated region (UTR), a 3′ UTR, and a poly (A) tail so as to have the following structure:
5′UTR-ORF encoding Gc of Heartland virus fused with COL1A1 signal peptide-3′UTR-poly (A) tail, and
wherein the ORF encoding Gc of Heartland virus fused with COL1A1 signal peptide has a nucleotide sequence of SEQ ID NO: 8.

### Claim 14 (depends on 10)

The Heartland virus vaccine composition according to claim 10, wherein the poly (A) tail has a length of 50-250 nucleotides.

### Claim 15 (depends on 11)

The Heartland virus vaccine composition according to claim 11, wherein the poly (A) tail has a length of 50-250 nucleotides.

### Claim 16 (depends on 12)

The Heartland virus vaccine composition according to claim 12, wherein the poly (A) tail has a length of 50-250 nucleotides.

### Claim 17 (depends on 13)

The Heartland virus vaccine composition according to claim 13, wherein the poly (A) tail has a length of 50-250 nucleotides.

### Claim 18 (depends on 10)

The Heartland virus vaccine composition according to claim 10, wherein the mRNA having the structure of 5′UTR-ORF encoding Gn of Heartland virus-3′UTR-poly (A) tail has a nucleotide sequence of SEQ ID NO: 9.

### Claim 19 (depends on 11)

The Heartland virus vaccine composition according to claim 11, wherein the mRNA having the structure of 5′UTR-ORF encoding Gc of Heartland virus-3′UTR-poly (A) tail has a nucleotide sequence of SEQ ID NO: 10.

### Claim 20 (depends on 12)

The Heartland virus vaccine composition according to claim 12, wherein the mRNA having the structure of 5′UTR-ORF encoding Gn of Heartland virus fused with COL1A1 signal peptide-3′UTR-poly (A) tail has a nucleotide sequence of SEQ ID NO: 11.

### Claim 21 (depends on 13)

The Heartland virus vaccine composition according to claim 13, wherein the mRNA having the structure of 5′UTR-ORF encoding Gc of Heartland virus fused with COL1A1 signal peptide-3′UTR-poly (A) tail has a nucleotide sequence of SEQ ID NO: 12.

### Claim 22 (depends on 10)

The Heartland virus vaccine composition according to claim 10, wherein the mRNA having the structure of 5′UTR-ORF encoding Gn of Heartland virus-3′UTR-poly (A) tail has a nucleotide sequence having at least 80% identity to SEQ ID NO: 9.

### Claim 23 (depends on 11)

The Heartland virus vaccine composition according to claim 11, wherein the mRNA having the structure of 5′UTR-ORF encoding Gc of Heartland virus-3′UTR-poly (A) tail has a nucleotide sequence having at least 80% identity to SEQ ID NO: 10.

### Claim 24 (depends on 12)

The Heartland virus vaccine composition according to claim 12, wherein the mRNA having the structure of 5′UTR-ORF encoding Gn of Heartland virus fused with COL1A1 signal peptide-3′UTR-poly (A) tail has a nucleotide sequence having at least 80% identity to SEQ ID NO: 11.

### Claim 25 (depends on 13)

The Heartland virus vaccine composition according to claim 13, wherein the mRNA having the structure of 5′UTR-ORF encoding Gc of Heartland virus fused with COL1A1 signal peptide-3′UTR-poly (A) tail has a nucleotide sequence having at least 80% identity to SEQ ID NO: 12.

### Claim 26 (depends on 1)

The Heartland virus vaccine composition according to claim 1 further comprising a pharmaceutically acceptable carrier.

### Claim 27 (depends on 26)

The Heartland virus vaccine composition according to claim 26, wherein the pharmaceutically acceptable carrier is a lipid nanoparticle encapsulating the mRNA therein.

### Claim 28 (depends on 1)

A method of inducing immune response against Heartland virus comprising:
administering an effective amount of the Heartland virus vaccine composition according to claim 1 to a subject in need thereof.
